|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
2011
|
|
gptkbp:ATCCode
|
gptkb:B01AF01
|
|
gptkbp:bioavailability
|
80-100%
|
|
gptkbp:brand
|
gptkb:Xarelto
|
|
gptkbp:CASNumber
|
366789-02-8
|
|
gptkbp:contraindication
|
active pathological bleeding
severe hypersensitivity to rivaroxaban
|
|
gptkbp:drugClass
|
gptkb:anticoagulant
|
|
gptkbp:drugInteraction
|
gptkb:phenytoin
gptkb:rifampin
gptkb:clarithromycin
gptkb:ritonavir
gptkb:carbamazepine
gptkb:ketoconazole
gptkb:St._John's_Wort
|
|
gptkbp:eliminationHalfLife
|
5-9 hours (young), 11-13 hours (elderly)
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
MUNRUTXBAQUQKT-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
gptkb:C19H18ClN3O5S
|
|
gptkbp:hasPharmacodynamics
|
inhibits free and clot-bound factor Xa and prothrombinase activity
|
|
gptkbp:hasSMILES
|
CC1=NN(C2=C1C=CC(=C2)Cl)C(=O)C3=CC=C(C=C3)S(=O)(=O)NC(=O)O
|
|
gptkbp:hasUNII
|
9N1LH5M5MR
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB06778
|
|
gptkbp:indication
|
prevention of venous thromboembolism after hip or knee replacement surgery
treatment of deep vein thrombosis
treatment of pulmonary embolism
prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation
|
|
gptkbp:legalStatus
|
prescription only
patented
|
|
gptkbp:manufacturer
|
gptkb:Bayer
gptkb:Janssen_Pharmaceuticals
|
|
gptkbp:mechanismOfAction
|
direct factor Xa inhibitor
|
|
gptkbp:metabolism
|
hepatic (CYP3A4, CYP2J2, CYP-independent mechanisms)
|
|
gptkbp:molecularWeight
|
435.88
|
|
gptkbp:name
|
gptkb:Rivaroxaban
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
92-95%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2010604
gptkb:DB06778
8056452
9875401
D08917
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
bleeding
|
|
gptkbp:status
|
true
|
|
gptkbp:synonym
|
gptkb:BAY_59-7939
|
|
gptkbp:target
|
coagulation factor Xa
|
|
gptkbp:bfsParent
|
gptkb:dimercaprol
|
|
gptkbp:bfsLayer
|
8
|